Knockdown of TBRG4 suppresses proliferation, invasion and promotes apoptosis of osteosarcoma cells by downregulating TGF-β1 expression and PI3K/AKT signaling pathway
- PMID: 32240636
- DOI: 10.1016/j.abb.2020.108351
Knockdown of TBRG4 suppresses proliferation, invasion and promotes apoptosis of osteosarcoma cells by downregulating TGF-β1 expression and PI3K/AKT signaling pathway
Abstract
Transforming growth factor beta regulator 4 (TBRG4) is a novel regulator in tumorigenic progression of several tumors. However, so far, the expression and functions of TBRG4 in osteosarcoma are unknown. The aim of this study was to investigate the potential biological functions of TBRG4 in osteosarcoma. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of TBRG4 in osteosarcoma tissues and cell lines. The levels of TBRG4 protein in osteosarcoma tissues were assessed by immunohistochemistry. Lentivirus-mediated short hairpin (sh) RNA was employed to knock down TBRG4 in osteosarcoma cells, and the expressions of TBRG4 mRNA and protein were determined by qRT-PCR and Western blot assay, respectively. Subsequently, the proliferation, clonogenic ability, apoptosis and invasion of osteosarcoma cells were measured using high content screening analysis and CCK8 assay, tumor sphere formation assay, flow cytometry and Transwell invasion assays, respectively. Furthermore, the osteosarcoma cells growth and metastasis in vivo were detected, and the effect of TBRG4 on the transforming growth factor β1 (TGF-β1) and PI3K/AKT signaling pathway was explored by qRT-PCR and Western blot assay, respectively. The results showed the levels of TBRG4 were overexpressed in osteosarcoma tissues and cell lines, confirming that the high TBRG4 expression was related to advanced tumor stages, large tumor size, and lymph node metastasis. Functional assays showed knockdown of TBRG4 could inhibit proliferation, invasion and induce apoptosis of osteosarcoma cells in vitro, and could also suppress osteosarcoma growth and metastasis in vivo. By examining the expression levels of TGF-β1, p-PI3K, PI3K, p-AKT and AKT, it showed that the suppression of TBRG4 would reduce TGF-β1 expression and inactivate the PI3K/AKT signaling pathway. These results showed for the first time that TBRG4 knockdown could suppress osteosarcoma progression, suggesting TBRG4 might be a promising therapeutic target for osteosarcoma treatment.
Keywords: Apoptosis; Invasion; Osteosarcoma; Proliferation; TBRG4.
Copyright © 2020. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors declare no conflicts of interest.
Similar articles
-
Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis.Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1418-1427. doi: 10.26355/eurrev_201902_17098. Eur Rev Med Pharmacol Sci. 2019. PMID: 30840262
-
SIX1 reduces the expression of PTEN via activating PI3K/AKT signal to promote cell proliferation and tumorigenesis in osteosarcoma.Biomed Pharmacother. 2018 Sep;105:10-17. doi: 10.1016/j.biopha.2018.04.028. Epub 2018 May 26. Biomed Pharmacother. 2018. PMID: 29807230
-
[Astragali Radix-Curcumae Rhizoma drug pair inhibits growth of osteosarcoma by affecting cell adhesion and angiogenesis via PI3K/Akt/HIF-1α pathway].Zhongguo Zhong Yao Za Zhi. 2025 Apr;50(8):2217-2228. doi: 10.19540/j.cnki.cjcmm.20241212.704. Zhongguo Zhong Yao Za Zhi. 2025. PMID: 40461231 Chinese.
-
New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis.Pathol Res Pract. 2023 Nov;251:154902. doi: 10.1016/j.prp.2023.154902. Epub 2023 Oct 21. Pathol Res Pract. 2023. PMID: 37922723 Review.
-
MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects.Tumour Biol. 2013 Aug;34(4):2093-8. doi: 10.1007/s13277-013-0940-7. Tumour Biol. 2013. PMID: 23797816 Review.
Cited by
-
Tumor suppressing role of serum-derived exosomal microRNA-15a in osteosarcoma cells through the GATA binding protein 2/murine double minute 2 axis and the p53 signaling pathway.Bioengineered. 2021 Dec;12(1):8378-8395. doi: 10.1080/21655979.2021.1987092. Bioengineered. 2021. PMID: 34592889 Free PMC article.
-
Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma.World J Gastroenterol. 2021 Jul 28;27(28):4667-4686. doi: 10.3748/wjg.v27.i28.4667. World J Gastroenterol. 2021. PMID: 34366628 Free PMC article.
-
Transcriptional patterns of cancer-related genes in primary and metastatic tumours revealed by machine learning.BMC Biol. 2025 Aug 7;23(1):246. doi: 10.1186/s12915-025-02339-z. BMC Biol. 2025. PMID: 40775769 Free PMC article.
-
FASTK family of genes linked to cancer.Bioinformation. 2022 Mar 31;18(3):206-213. doi: 10.6026/97320630018206. eCollection 2022. Bioinformation. 2022. PMID: 36518140 Free PMC article.
-
Comprehensive analysis of regulatory B Cell related genes in prognosis and therapeutic response in lung adenocarcinoma.Front Immunol. 2025 Jul 30;16:1595408. doi: 10.3389/fimmu.2025.1595408. eCollection 2025. Front Immunol. 2025. PMID: 40808964 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical